Dominique Costantini
Fondatore presso OSE IMMUNOTHERAPEUTICS
Posizioni attive di Dominique Costantini
Società | Posizione | Inizio | Fine |
---|---|---|---|
OSE IMMUNOTHERAPEUTICS | Presidente | 12/04/2018 | - |
Fondatore | 17/11/2004 | - | |
Corporate Officer/Principal | - | - | |
Direttore/Membro del Consiglio | 17/11/2004 | 12/04/2018 | |
Amministratore Delegato | 16/01/2022 | 13/07/2022 | |
Only For Children Pharmaceuticals SA | Direttore/Membro del Consiglio | - | - |
Smart Immune SAS
Smart Immune SAS BiotechnologyHealth Technology Smart Immune SAS is a clinical-stage biotechnology company based in Paris, France. Smart Immune is developing Protcell, a thymus-empowered T cell progenitor therapy platform to re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies for all. The French company aims to improve outcomes for patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. Smart Immune has ongoing collaborations with leading institutions in the EU and the US. Smart101 is already in phase I/II clinical trials in the EU and the US, looking at the acceleration of complete immune recovery in patients fighting cancer and infection and undergoing allogeneic hematopoietic stem cell transplantation. Smart Immune is also developing therapies using gene-modified T cell progenitors through its Protcell platform to provide targeted treatments against cancer, like persistent off-the-shelf CAR T cells. The company is headquartered at Biotech Santé. The company was founded in 2017 by Karine Rossignol, Marina Cavazzana, Isabelle André, with Karine Rossignol as the CEO since 2017. | Direttore/Membro del Consiglio | - | - |
Independent Dir/Board Member | - | - |
Storia della carriera di Dominique Costantini
Precedenti posizioni note di Dominique Costantini
Società | Posizione | Inizio | Fine |
---|---|---|---|
THERANEXUS | Direttore/Membro del Consiglio | 27/09/2017 | 01/01/2020 |
Independent Dir/Board Member | 27/09/2017 | 01/01/2020 | |
ABIVAX | Direttore/Membro del Consiglio | 15/09/2015 | 21/12/2018 |
Independent Dir/Board Member | 15/09/2015 | 21/12/2018 | |
VALERIO THERAPEUTICS | Amministratore Delegato | 05/03/1997 | 29/06/2011 |
Presidente | 05/03/1997 | 15/07/2010 | |
Fondatore | 05/03/1997 | 29/06/2011 | |
OSE Pharmaceuticals | Amministratore Delegato | 01/01/2012 | - |
Fondatore | 01/01/2012 | - | |
SENSORION | Direttore/Membro del Consiglio | 31/05/2017 | - |
Independent Dir/Board Member | 31/05/2017 | - | |
THERADIAG | Direttore/Membro del Consiglio | 01/03/2017 | - |
Independent Dir/Board Member | 01/03/2017 | - | |
░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░ ░░░ | ░░░░░░░░ | - | - |
░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░ ░░░░░░░ ░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░ | ░░░░░░░░░░ | - |
Formazione di Dominique Costantini
Statistiche
Distribuzione geografica
Francia | 15 |
Belgio | 2 |
Posizioni
Director/Board Member | 10 |
Independent Dir/Board Member | 6 |
Chief Executive Officer | 4 |
Settori
Health Technology | 13 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 7 |
---|---|
VALERIO THERAPEUTICS | Health Technology |
SANOFI | Health Technology |
AB SCIENCE | Health Technology |
THERANEXUS | Health Technology |
ABIVAX | Health Technology |
OSE IMMUNOTHERAPEUTICS | Health Technology |
SENSORION | Health Technology |
Aziende private | 8 |
---|---|
Université de Paris 5 René Descartes | Consumer Services |
Orphan Synergy Europe-Pharma SA
Orphan Synergy Europe-Pharma SA Pharmaceuticals: MajorHealth Technology Orphan Synergy Europe-Pharma SA engages in the development of immunotherapy products against late stage cancer. Its products include Tedopi as treatment for lung cancer and Memopi technology which helps the immune system to eliminate malignant cells. The company was founded by Dominique Costantini and Emile Loria on November 17, 2004 and is headquartered in Paris, France. | Health Technology |
CarThera SAS
CarThera SAS Medical SpecialtiesHealth Technology CarThera SAS develops ultrasound based medical devices to treat brain disorders. The firm offers SonoProbe and SonoCloud. The company was founded by Alexandre Carpentier on February 8, 2010 and is headquartered in Paris, France. | Health Technology |
Only For Children Pharmaceuticals SA | |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Health Technology |
Theradiag SA
Theradiag SA Medical SpecialtiesHealth Technology Theradiag SA engages in the distribution, development, and manufacturing of in vitro diagnostic and theranostics tests. It operates through the following segments: Theranostics and Diagnostics. The Theranostics segment offers solutions for patients treated with anti-tumour necrosis factor alpha. The Diagnostics segment includes products for anti-immunity, genetics, allergy, infectious disease, drug of abuse, other diagnoses, and instrumentation. The company was founded on December 29, 1986 and is headquartered in Croissy-Beaubourg, France. | Health Technology |
OSE Pharmaceuticals | |
Smart Immune SAS
Smart Immune SAS BiotechnologyHealth Technology Smart Immune SAS is a clinical-stage biotechnology company based in Paris, France. Smart Immune is developing Protcell, a thymus-empowered T cell progenitor therapy platform to re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies for all. The French company aims to improve outcomes for patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. Smart Immune has ongoing collaborations with leading institutions in the EU and the US. Smart101 is already in phase I/II clinical trials in the EU and the US, looking at the acceleration of complete immune recovery in patients fighting cancer and infection and undergoing allogeneic hematopoietic stem cell transplantation. Smart Immune is also developing therapies using gene-modified T cell progenitors through its Protcell platform to provide targeted treatments against cancer, like persistent off-the-shelf CAR T cells. The company is headquartered at Biotech Santé. The company was founded in 2017 by Karine Rossignol, Marina Cavazzana, Isabelle André, with Karine Rossignol as the CEO since 2017. | Health Technology |
- Borsa valori
- Insiders
- Dominique Costantini
- Esperienza